Patents Assigned to Daiichi Sankyo Company, Limited
  • Publication number: 20200282073
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Application
    Filed: March 24, 2020
    Publication date: September 10, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
  • Patent number: 10768179
    Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: September 8, 2020
    Assignees: National Cancer Center, Daiichi Sankyo Company, Limited
    Inventors: Takashi Kohno, Hideaki Ogiwara, Yuichi Tominaga, Saito Higuchi
  • Patent number: 10765738
    Abstract: The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 8, 2020
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company Limited
    Inventors: Reimar Abraham, Mauricio Redondo-Müller
  • Patent number: 10758554
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: September 1, 2020
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko Endo, Kyohei Takahashi, Shinya Umezaki
  • Patent number: 10752647
    Abstract: There is a need for a new antibiotic having a novel mechanism of action, which exhibits strong antibacterial activity not only against sensitive bacteria, but also against resistant bacteria thereof, and at the same time possess excellent solubility and safety profile amenable to human use. As a result of intensive research, the present inventors have found that N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives represented by general formula (I), a regioisomer, a stereoisomer, or a pharmaceutically acceptable salt thereof possess excellent solubility and safety profile for use in human for the treatment of bacterial infectious diseases.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 25, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Manoj Kumar Khera, Naresh Chintaman Dumbre, Pasha Khan
  • Publication number: 20200261594
    Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 20, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
  • Publication number: 20200262917
    Abstract: Provided is a novel composition. Provided is a composition for cytotoxic T cell depletion, comprising an anti-LAG-3 antibody or a binding fragment thereof having the properties described in (i) to (iii) below: (i) having in vitro ADCC activity; (ii) reducing, in a low fucose form, the number of LAG-3 positive cells in vivo; and (iii) binding to activated human T cells.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 20, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Naoki Kiyosawa, Shinnosuke Yamada
  • Patent number: 10730876
    Abstract: The present disclosure provides processes for the preparation of a compound of formula I: or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 4, 2020
    Assignees: Plexxikon Inc., Daiichi Sankyo Company, Limited
    Inventors: Prabha N. Ibrahim, Masayoshi Jin, Shinji Matsuura
  • Patent number: 10731159
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: August 4, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
  • Patent number: 10729782
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 4, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
  • Publication number: 20200239425
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Application
    Filed: April 9, 2020
    Publication date: July 30, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10723800
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 28, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda
  • Publication number: 20200231654
    Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
    Type: Application
    Filed: July 17, 2018
    Publication date: July 23, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
  • Patent number: 10716790
    Abstract: It is intended to provide a medicament and a method for treating cancer comprising a compound having MDM2 inhibiting activity and a compound having FLT3 inhibiting activity in combination. The present invention provides a medicament comprising (3?R,4?S,5?R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6?-chloro-4?-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2?-oxo-1?,2?-dihydrodispiro[cyclohexane-1,2?-pyrrolidine-3?,3?-indole]-5?-carboxamide or a pharmaceutically acceptable salt thereof and N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof in combination, and a treatment method using these compounds or salts in combination.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 21, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Takahiko Seki
  • Publication number: 20200216433
    Abstract: The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 9, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Mitsuhiro Makino, Kaori Ito, Seiko Nagata, Hirasawa Makoto
  • Publication number: 20200207837
    Abstract: The present invention provides a novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
    Type: Application
    Filed: September 6, 2018
    Publication date: July 2, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Masakazu Tamura
  • Publication number: 20200199179
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.
    Type: Application
    Filed: January 30, 2020
    Publication date: June 25, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • Publication number: 20200172494
    Abstract: Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein, X represents a carboxyl group or a tetrazolyl group; Q represents a C1-C3 alkylene group, an oxygen atom, a sulfur atom, etc.; G represents a phenyl group where the phenyl group may have 1 to 3 substituents independently selected from the group consisting of a halogen atom, a cyano group, a C1-C6 alkyl group, etc.
    Type: Application
    Filed: December 26, 2017
    Publication date: June 4, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yasuyuki Takeda, Yamato Suzuki, Toshiharu Noji, Hidenobu Murafuji, Satoshi Muneoka, Hidekazu Inoue, Bitoku Takahashi, Rie Inaba
  • Publication number: 20200173999
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Application
    Filed: December 25, 2017
    Publication date: June 4, 2020
    Applicants: KINKI UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • Publication number: 20200171163
    Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 4, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko SAITO, Tsuyoshi HIRATA, Kensuke NAKAMURA